NFCR Writer David Perry, Author at NFCR - Page 4 of 9

NFCR Writer David Perry

Mary-Claire King: Sharpshooter with Breast Cancer in Her Sights

Cancer is complex. “Simple” is the last word that either layman or scientist would use to describe virtually any aspect of the disease. However, simply put, the health prospects of women worldwide have improved as a result of the laboratory work of Mary-Claire King, Ph.D., winner of the National Foundation…...

Read more

HPV Vaccine Gets Expanded Approval from FDA

The U.S. Food and Drug Administration (FDA) recently approved Gardasil 9, a human papilloma virus (HPV) vaccine, for adults aged 27 to 45. The move could help further spell the end of one of the main causes of a host of communicable cancers. Already approved for patients aged 9 to…...

Read more

Hormone Therapy: Influencing Breast Cancer Treatment and Beyond

While recent medical discoveries, from drugs to imaging techniques, continue to revolutionize cancer care, none of them would be possible without foundations having been laid years, or even decades, earlier. Groundbreaking work by the late endocrinologist Jack Gorski, Ph.D., who passed away in 2006 and was funded by the National…...

Read more

The Muscle Cancer That Isn’t

In a proof-positive that cancer research still has miles to cover, a pediatric cancer long associated with aberrant muscle cells has now been found to arise from cells that would normally develop into cells lining blood vessels. Oncologists at St. Jude Children’s Research Hospital researching rhabdomyosarcoma, the most prevalent soft…...

Read more

Early Cancer Screening 101

True fact: It was nearly a century ago, in 1924, when a Johns Hopkins doctor by the apt name of John Bloodgood predicted in a New York Times editorial that early detection of cancer would wipe the disease form humanity in one fell swoop. As of yet, that particular future…...

Read more

Bea Mintz: The Pioneer of Transgenics—and So Much More

Changing a cancerous cell into a normal cell would seem to be the very definition of a holy grail: a lofty goal that is all but impossible to achieve. And yet, it has already been done. It was 1975 when the seminal work of Dr. Beatrice (“Bea”) Mintz showed how…...

Read more

Crizotinib Plus Radiation May Reduce NF2-Related Hearing Loss

A study co-authored by National Foundation for Cancer Research Fellow Dr. Rakesh Jain hints that adding the cancer drug crizotinib to the radiation therapy for tumors associated with neurofibromatosis 2 (NF2) may lessen the hearing loss that often precipitates from radiotherapy. Although not a cancer, NF2 is characterized by benign…...

Read more

Targeted Lung Cancer Therapy

A Match Made Possible A discovery by a team led by Massachusetts General Hospital’s Daniel Haber, M.D., Ph.D., a physician-scientist supported by the National Foundation for Cancer Research since 2003, now represents a source of hope for many patients with metastatic lung cancer. He and his colleagues correctly linked very…...

Read more

New Type of Lung Cancer Identified

A research team at Cold Spring Harbor Laboratory discovered a new kind of small-cell lung cancer (SCLC). While the general public may not consider this particularly good news, the identification paves the way for developing more specific and personalized medicine approaches to target this previously unnoticed form of the disease....

Read more

November Is Pancreatic Cancer Awareness Month

Even in the company of other vicious diseases, pancreatic cancer is particularly nasty: The one-year relative survival rate is 20% and the five-year rate is 7%. It ranks third in cancer-related deaths in the United States, and it is expected that over 55,000 Americans will be diagnosed this year alone.…...

Read more